{"entity":{"id":"paper-cpx-351-study-301-lancet-je-jco-2018","kind":"paper","name":"CPX-351 versus 7+3 chemotherapy in older adults with newly diagnosed secondary acute myeloid leukaemia","aka":[],"tldr":"A liposomal formulation locking cytarabine and daunorubicin in a fixed ratio lengthened survival compared with standard 7+3 chemotherapy in patients aged 60 to 75 with secondary or therapy-related acute myeloid leukaemia, and more of them reached transplant.","summary":"Phase 3 trial of 309 patients aged 60 to 75 with newly diagnosed high-risk or secondary AML randomised to CPX-351 or conventional cytarabine plus daunorubicin (7+3).\n\nMedian overall survival was 9.56 months with CPX-351 against 5.95 months with 7+3 (hazard ratio 0.69); remission rates were higher and outcomes after transplant were better, with a longer recovery of blood counts as the main cost.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2018","url":"https://doi.org/10.1200/JCO.2017.77.6112"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30024784/"}],"tags":[],"related":[],"cancers":["aml-secondary"],"sections":[],"technologies":[],"targets":[],"drugs":["cytarabine","daunorubicin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2018,"doi":"10.1200/JCO.2017.77.6112","pmid":"30024784","authors":"Lancet JE, Uy GL, Cortes JE, et al.","paperType":"rct","findings":["Median overall survival 9.56 vs 5.95 months; hazard ratio 0.69.","Complete remission (with or without incomplete recovery) 47.7 percent vs 33.3 percent."],"whatItMeans":"CPX-351 is the preferred intensive induction for fit older patients with secondary or therapy-related AML in many centres, mainly as a bridge to allogeneic transplant.","caveats":["Open-label; longer neutropenia and thrombocytopenia with CPX-351.","Benefit in patients under 60 and in de novo AML is not established."],"changedPractice":true,"participants":309},"route":"/key-papers/paper-cpx-351-study-301-lancet-je-jco-2018/","neighbours":{"cancer":[{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/"}],"drug":[{"id":"cytarabine","kind":"drug","name":"Cytarabine","route":"/drugs/cytarabine/"},{"id":"daunorubicin","kind":"drug","name":"Daunorubicin","route":"/drugs/daunorubicin/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}